{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T16:23:24Z","timestamp":1648916604061},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.beha.2011.09.003","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T10:54:48Z","timestamp":1321440888000},"page":"485-488","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of prognostic factors in AML"],"prefix":"10.1016","volume":"24","author":[{"given":"Jacob M.","family":"Rowe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2011.09.003_bib1","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2011.09.003_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.beha.2010.09.017","article-title":"Epigenetics in AML","volume":"23","author":"Melnick","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2011.09.003_bib3","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.09.003_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.beha.2010.09.007","article-title":"The evolving paradigm of prognostic factors in AML: introduction to the Acute Leukemia Forum 2010","volume":"23","author":"Rowe","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2011.09.003_bib5","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2010-05-260117","article-title":"How I treat acute myeloid leukemia","volume":"116","author":"Rowe","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.09.003_bib6","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2004-08-2977","article-title":"Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222","volume":"105","author":"Moore","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.09.003_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.09.003_bib8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2011.09.003_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"Buchner","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.09.003_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V114.22.790.790","volume":"114","author":"Petersdorf","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.09.003_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.beha.2010.09.012","article-title":"Has there been progress in the treatment of older patients with acute myeloid leukemia?","volume":"23","author":"Erba","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2011.09.003_bib12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.09.003_bib13","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2011.09.003_bib14","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2011.09.003_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.beha.2011.09.012","article-title":"Research and discovery of the first human cancer virus, HTLV-1","volume":"24","author":"Gallo","year":"2011","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T14:46:23Z","timestamp":1593269183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1521692611000831"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.09.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}